Cytotoxic Drugs Contract Manufacturing Market | Coherent Market Insights - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Cytotoxic Drugs Contract Manufacturing Market | Coherent Market Insights

Description:

Read here the latest updates on the Cytotoxic Drugs Contract Manufacturing Market published by the CMI team. – PowerPoint PPT presentation

Number of Views:12
Date added: 18 August 2020
Slides: 12
Provided by: adwaitcoherent

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Cytotoxic Drugs Contract Manufacturing Market | Coherent Market Insights


1
Coherent Marketing Insights
  • Market Research Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • Covid-19 Impact Tracker

2
  • CYTOTOXIC DRUGS CONTRACT MANUFACTURING MARKET
    ANALYSIS
  • Cytotoxic Drugs Contract Manufacturing Market, by
    Production Scale (Industrial Scale, Pilot Scale,
    and Laboratory Scale), by Form (Liquid, and
    Solid), by Product Type (Oral and Intravenous),
    and by Region (North America, Latin America,
    Europe, Asia Pacific, Middle East, and Africa) -
    Size, Share, Outlook, and Opportunity Analysis,
    2019 - 2027

3
  • Global Cytotoxic Drugs Contract Manufacturing
    Market, by Production Scale (Industrial Scale,
    Pilot Scale, and Laboratory Scale), by Form
    (Liquid, and Solid), by Product Type (Oral and
    Intravenous), and by Region (North America, Latin
    America, Europe, Asia Pacific, Middle East, and
    Africa), was valued at US 6,285.2 million in
    2018, and is expected to exhibit a CAGR of 9.1
    over the forecast period (2019-2027), as
    highlighted in a new report published by .
    Governments in emerging economies such as India
    are focusing on initiatives to increase domestic
    production. For instance, in August 2017,
    according to the Department of Pharmaceuticals
    under the Ministry of Chemicals and Fertilizers
    of government of India proposed 'peak customs
    duty' and suggested setting up of bulk drug parks
    to increase domestic production.

4
  • Furthermore, rapid growth in the pharmaceutical
    industry in the Asia Pacific region is expected
    to propel growth of cytotoxic drug contract
    manufacturing market in the Asia Pacific region
    during the forecast period. For instance, in
    September 2019, according to the Indian Brand
    Equity Foundation (IBEF), India pharmaceutical
    industry is expected to reach US 55 Bn by 2020.
    Increasing investment by the market players, in
    order to expand their service and product
    offerings is expected to boost growth of the
    cytotoxic drugs contract manufacturing market
    over the forecast period. For instance, in
    October 2017, Lonza Group established Lonza
    Collaborative Innovation Center (CIC) in new Life
    Science Park in Haifa, Israel. With this, Lonza
    aims to accelerate leading RD projects across
    Lonza's Pharma Biotech segment, and tap into
    potentially transformative biological and
    manufacturing capabilities.

5
  • North America is expected to dominate cytotoxic
    drugs contract manufacturing market over the
    forecast period, owing to adoption of growth
    strategies such as product launches, investments,
    facility expansion by the market players in the
    region to expand their market presence. For
    instance, in 2016, Cambrex, a leading small
    molecule API contract manufacturer expanded its
    facility at Iowa, Charles City-based
    manufacturing site, adding 1,000- and 4,000
    gallon glass-lined reactors in 7,500-square-foot
    plant. Moreover, market players are focused on
    collaboration and acquisition strategies to
    expand their market presence and enhance facility
    in the region, which is expected to drive growth
    of the market over the forecast period. For
    instance, in November 2017, CordenPharma
    International, a contract provider of both
    small-molecule APIs and drug products acquired a
    Hospira Boulder facility from Pfizer Inc., a
    54,000-square-foot API manufacturing facility
    located in Colorado, U.S. to build its
    capabilities in high-potency manufacturing.
    According to the expansion strategy, the new
    facility specializes in development, scale-up,
    optimization, and production of highly potent and
    cytotoxic/cytostatic APIs from development to
    commercialization stage.

6
Key Takeaways of the Cytotoxic Drugs Contract
Manufacturing Market
  • The global cytotoxic drugs contract manufacturing
    market is expected to exhibit a CAGR of 1 over
    the forecast period, owing to increasing adoption
    of collaboration and acquisition strategies by
    key players and rising trend of contact
    manufacturing. Contract development and
    manufacturing organizations (CDMOs) play a vital
    role in expediting development of innovative
    small molecule drug candidates, as these
    important development activities are often
    achieved through outsourcing partnerships with
    CDMOs
  • Among form, liquid segment held dominant position
    in the cytotoxic drugs contract manufacturing
    market in 2018, owing to adoption of expansion
    strategies by the market players. For instance,
    in April 2018, STA Pharmaceutical, a subsidiary
    of WuXi AppTec, signed an investment agreement
    with the Government of Shanghai, to build a new
    research development (RD) center for APIs and
    intermediates located next to the companys
    existing Jinshan drug-substance manufacturing
    site.

7
  • Among product type, intravenous segment held
    dominant position in the cytotoxic drugs contract
    manufacturing market in 2018, owing to companies
    focusing on expansion of their manufacturing
    facilities for production of sterile injectable
    and API, in order to increase client base and
    cater to their demand. For instance, in March
    2017, Piramal Pharma Solutions expanded
    manufacturing capabilities in Lexington, U.S. The
    new facility includes installation of a new
    high-speed vial filling line, expansion of the
    state-of-the art laboratories, and associated
    utility support.
  • Companies operating in the global cytotoxic drugs
    contract manufacturing market include Lonza
    Group, Piramal Group, Evonik Industries AG,
    Novasep Holding SAS, Merck KGaA (SAFC Pharma),
    Baxter Biopharma Solutions, AbbVie Contract
    Manufacturing, Cambrex Corporation, BSP
    Pharmaceuticals S.p.A., CordenPharma
    International, Catalent, Inc., Albany Molecular
    Research Inc., Evotec, WuXi AppTec Co., Ltd.,
    Pierre Fabre Laboratories, and Dishman Group

8
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Referance https//www.coherentmarketinsights.com/
    market-insight/cytotoxic-drugs-contract-manufactur
    ing-market-3175

9
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions. We are headquartered
    in India, having office at global financial
    capital in the U.S. Our client base includes
    players from across all business verticals in
    over 150 countries worldwide.
  • What We ProvideCustomized Market Research
    AnalysisIndustry Analysis ServicesBusiness
    Consulting ServicesLong Term Engagement
    ModelCountry Specific Analysis

10
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt. LTD.Coherent
    Market Insights 1001 4th Ave, 3200 Seattle, WA
    98154, U.S.Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

11
Thank You
  • Kindly Follow CMI Social Media Profiles for the
    latest Company Updates.
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com